Lumos Diagnostics Holdings Ltd (LDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lumos Diagnostics Holdings Ltd (LDX) has a cash flow conversion efficiency ratio of 0.149x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$778.03K ≈ $550.51K USD) by net assets (AU$5.24 Million ≈ $3.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Lumos Diagnostics Holdings Ltd (LDX) balance sheet quality index to measure how much of total assets are equity-financed.
Lumos Diagnostics Holdings Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Lumos Diagnostics Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow reinvestment rate of Lumos Diagnostics Holdings Ltd to assess the company's total reinvestment commitment from operating cash flow.
Lumos Diagnostics Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lumos Diagnostics Holdings Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FineMat Applied Materials Co Ltd
TW:6698
|
-0.033x |
|
Oceanic Iron Ore Corp
V:FEO
|
0.004x |
|
Streamex Corp
NASDAQ:STEX
|
-0.023x |
|
AGROB Immobilien AG
F:AGR
|
N/A |
|
Moorim P&P Co Ltd
KO:009580
|
0.011x |
|
Speciality Restaurants Limited
NSE:SPECIALITY
|
0.091x |
|
Thanapiriya Public Company Limited
BK:TNP
|
0.060x |
|
HEMARAJ INDUSTRIAL PROPERTY AND LEASEHOLD FUND
BK:HPF
|
0.018x |
Annual Cash Flow Conversion Efficiency for Lumos Diagnostics Holdings Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Lumos Diagnostics Holdings Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Lumos Diagnostics Holdings Ltd (LDX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$6.16 Million ≈ $4.36 Million |
AU$-9.33 Million ≈ $-6.60 Million |
-1.516x | -1239.24% |
| 2023-12-31 | AU$7.11 Million ≈ $5.03 Million |
AU$946.00K ≈ $669.36K |
0.133x | +113.11% |
| 2022-12-31 | AU$9.50 Million ≈ $6.72 Million |
AU$-9.64 Million ≈ $-6.82 Million |
-1.015x | -0.62% |
| 2021-12-31 | AU$17.89 Million ≈ $12.65 Million |
AU$-18.04 Million ≈ $-12.76 Million |
-1.008x | -439.75% |
| 2020-12-31 | AU$58.28 Million ≈ $41.24 Million |
AU$-10.89 Million ≈ $-7.70 Million |
-0.187x | -10.16% |
| 2019-12-31 | AU$22.16 Million ≈ $15.68 Million |
AU$-3.76 Million ≈ $-2.66 Million |
-0.170x | +34.83% |
| 2018-12-31 | AU$11.66 Million ≈ $8.25 Million |
AU$-3.03 Million ≈ $-2.15 Million |
-0.260x | -168.72% |
| 2017-12-31 | AU$2.98 Million ≈ $2.11 Million |
AU$-288.67K ≈ $-204.25K |
-0.097x | -- |
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, … Read more